ZyVersa’s lead anti-inflammatory candidate is a novel monoclonal antibody targeting the ASC component of inflammasomes, inhibiting both the intracellular and extracellular inflammatory response cascade for treatment of people with debilitating inflammatory diseases
ZyVersa’s lead anti-inflammatory candidate is a novel monoclonal antibody targeting the ASC component of inflammasomes, inhibiting both the intracellular and extracellular inflammatory response cascade for treatment of people with debilitating inflammatory diseases
WESTON, Fla., May 21, 2019 /PRNewswire/ -- ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for inflammatory and renal diseases, is pleased to announce formation of its inaugural Immunology Scientific Advisory Board comprised of some of the world’s leading experts in inflammasome research. The Immunology SAB will serve as strategic and scientific advisors to ZyVersa as it advances development of IC 100, our proprietary inflammasome inhibitor uniquely targeting ASC, and as we expand our inflammasome technology platform. The inaugural members of ZyVersa’s Immunology Scientific Advisory Board are listed below.
Robert W. Keane, Ph.D.
Professor, Physiology and Biophysics, Neurological Surgery and Microbiology, and Immunology, University of Miami Miller School of Medicine
The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine
Juan Pablo de Rivero Vaccari, Ph.D.
Research Assistant Professor, Department of Neurological Surgery, University of Miami Miller School of Medicine
The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine
Distinguished Faculty Member of The Center for Cognitive Neuroscience and Aging, University of Miami Miller School of Medicine
Associate Editor, Frontiers in Molecular Neuroscience
W. Dalton Dietrich, III, Ph.D.
Kinetic Concepts Distinguished Chair in Neurosurgery, and Scientific Director at The Miami Project to Cure Paralysis, the University of Miami Miller School of Medicine
Senior Associate Dean for Discovery Science and Co-Director of the Institute for Neural Engineering, University of Miami Miller School of Medicine
Professor, Neurological Surgery, Neurology, Biomedical Engineering, and Cell Biology, University of Miami Miller School of Medicine
Helen Bramlett
Professor, Department of Neurological Surgery, University of Miami Miller School of Medicine
The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine
Daniel G. Baker, MD
Former Vice President, Immunology Research and Development, Janssen Pharmaceutical Companies of Johnson & Johnson
Miguel S. Barbosa, Ph.D.
Former Global Head and Vice President of Immunology Research and External Innovation at Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson
William F. Bennett, Ph.D.
Principal, Bioscope Associates
Formerly: Genentech, Sensus Corporation, Cor Therapeutics
Douglas H. Farrar
CEO, Flatirons Biotech, Inc.
Former Cofounder and Chief Technical Officer, Coherus Biosciences
Alan Herman, Ph.D.
Chairman Emeritus, former Chief Scientific Officer, Coherus BioSciences
Formerly: Genentech, Amgen, Merck, Coherus BioSciences
To review the biographies of our scientific advisors, Click Here.
“We are privileged to have the opportunity to work with experts on the cutting edge of inflammasome research to support development of our novel inflammasome inhibitor, and more broadly our inflammasome technology platform,” stated Stephen Glover, Co-founder, Chief Executive Officer, and President of ZyVersa Therapeutics. “The unparalleled expertise of this group will enable optimization of our inflammasome program, which has potential to transform treatment of debilitating inflammatory diseases. We are thrilled to welcome these individuals to our team.”
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our clinical pipeline includes a phase 2a-ready asset, VAR 200, a cholesterol efflux mediator for treatment of focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases. For more information, please visit www.zyversa.com or contact the following:
View original content to download multimedia:http://www.prnewswire.com/news-releases/experts-on-the-forefront-of-inflammasome-research-will-serve-on-zyversa-therapeutics-inaugural-immunology-scientific-advisory-board-300853650.html
SOURCE ZyVersa Therapeutics, Inc.
